STEAP1 and neoplasm: Recently, we have provided evidence that PD-1 blockade in combination with a ChAdOx1-MVA immunisation regime against STEAP1 antigen is successful in improving survival and reducing tumour burden in a transplantable mouse model of prostate cancer [17].